MX337893B - Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. - Google Patents
Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion.Info
- Publication number
- MX337893B MX337893B MX2012005399A MX2012005399A MX337893B MX 337893 B MX337893 B MX 337893B MX 2012005399 A MX2012005399 A MX 2012005399A MX 2012005399 A MX2012005399 A MX 2012005399A MX 337893 B MX337893 B MX 337893B
- Authority
- MX
- Mexico
- Prior art keywords
- nanosuspension
- poorly soluble
- soluble drug
- microfluidization process
- drug made
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan las composiciones y los métodos para la preparación y administración de una nanosupensión oral con biodisponibilidad mejorada de un fármaco débilmente soluble. El método se optimiza por el proceso de microfluidización con excipientes poliméricos solubles en agua, en ausencia de agentes tensoactivos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25990309P | 2009-11-10 | 2009-11-10 | |
PCT/US2010/055897 WO2011059931A2 (en) | 2009-11-10 | 2010-11-09 | Nanosuspension of a poorly soluble drug via microfluidization process |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012005399A MX2012005399A (es) | 2012-08-03 |
MX337893B true MX337893B (es) | 2016-03-28 |
Family
ID=43903929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012005399A MX337893B (es) | 2009-11-10 | 2010-11-09 | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
Country Status (7)
Country | Link |
---|---|
US (2) | US9023886B2 (es) |
EP (1) | EP2498753B1 (es) |
JP (1) | JP6310636B2 (es) |
CA (1) | CA2780292A1 (es) |
ES (1) | ES2727733T3 (es) |
MX (1) | MX337893B (es) |
WO (1) | WO2011059931A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2780292A1 (en) | 2009-11-10 | 2011-05-19 | Celgene Corporation | Nanosus pens ion of a poorly soluble drug made by microfluidization process |
CN103391770A (zh) * | 2011-01-10 | 2013-11-13 | 细胞基因公司 | 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型 |
WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
SG11201400632YA (en) * | 2011-09-14 | 2014-04-28 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
WO2013119607A2 (en) * | 2012-02-08 | 2013-08-15 | Celgene Corporation | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
JP6336246B2 (ja) * | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | ナノ粒子化製剤及びその製造方法 |
EP3204046A4 (en) * | 2014-10-09 | 2018-08-08 | Andreas Voigt | Use of meso-and nanoporous material for surfactant trapping in nanoparticle suspensions |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
US5091187A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
GB9226905D0 (en) | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
JP3883228B2 (ja) * | 1995-03-02 | 2007-02-21 | 住化武田農薬株式会社 | 農薬組成物およびその製造法 |
AU719085B2 (en) * | 1996-08-22 | 2000-05-04 | Rtp Pharma Corporation | Processes of preparing or stabilising microparticles |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
AU743024B2 (en) * | 1997-03-05 | 2002-01-17 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
EP1276465B1 (en) * | 2000-04-20 | 2014-03-12 | Jagotec AG | Improved water-insoluble drug particle process |
AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
JP2002092094A (ja) * | 2000-09-12 | 2002-03-29 | Teijin Ltd | 分散型生産販売管理システム及びその方法 |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
BR0315316A (pt) * | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
KR20070007945A (ko) | 2004-04-23 | 2007-01-16 | 셀진 코포레이션 | 폐 고혈압증의 치료 및 관리를 위한 pde4 조절인자의사용 방법 및 그를 포함하는 조성물 |
JP4173471B2 (ja) * | 2004-09-06 | 2008-10-29 | 株式会社リコー | 情報管理システム、情報管理方法、記録媒体、および、情報管理プログラム |
WO2006062875A1 (en) | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
ATE554751T1 (de) * | 2007-07-13 | 2012-05-15 | Bend Res Inc | Nanopartikel mit einem nicht ionisierbaren polymer und einem anionischen zellulosepolymer |
WO2009042114A2 (en) * | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
CA2780292A1 (en) | 2009-11-10 | 2011-05-19 | Celgene Corporation | Nanosus pens ion of a poorly soluble drug made by microfluidization process |
-
2010
- 2010-11-09 CA CA2780292A patent/CA2780292A1/en not_active Abandoned
- 2010-11-09 US US12/942,930 patent/US9023886B2/en active Active
- 2010-11-09 WO PCT/US2010/055897 patent/WO2011059931A2/en active Application Filing
- 2010-11-09 EP EP10776917.6A patent/EP2498753B1/en active Active
- 2010-11-09 MX MX2012005399A patent/MX337893B/es active IP Right Grant
- 2010-11-09 ES ES10776917T patent/ES2727733T3/es active Active
- 2010-11-09 JP JP2012538876A patent/JP6310636B2/ja active Active
-
2015
- 2015-04-01 US US14/676,709 patent/US9616019B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2727733T3 (es) | 2019-10-18 |
WO2011059931A9 (en) | 2011-09-01 |
US9616019B2 (en) | 2017-04-11 |
CA2780292A1 (en) | 2011-05-19 |
US9023886B2 (en) | 2015-05-05 |
US20150265534A1 (en) | 2015-09-24 |
EP2498753B1 (en) | 2019-03-06 |
JP2013510855A (ja) | 2013-03-28 |
MX2012005399A (es) | 2012-08-03 |
EP2498753A2 (en) | 2012-09-19 |
JP6310636B2 (ja) | 2018-04-11 |
WO2011059931A2 (en) | 2011-05-19 |
WO2011059931A3 (en) | 2011-07-14 |
US20110124702A1 (en) | 2011-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX337893B (es) | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. | |
EP2458990A4 (en) | METHODS OF PRODUCING LYOPHILIZED PHARMACEUTICAL FORMULATIONS WITH HIGH CONCENTRATION | |
WO2011103150A3 (en) | Lyophilized preparations of bendamustine | |
MX355036B (es) | Vacunas combinadas de nanovehículos sintéticos. | |
MY174001A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
MX356210B (es) | Formulaciones de polimero acrilico. | |
EP2493457A4 (en) | SOLID DOSAGE FORM WITH RAPID DISSOLUTION | |
IL220679A (en) | Method of manufacture of solid preparations containing basic active pharmaceutical ingredients and the solid preparations produced by the method | |
UA102128C2 (en) | Nalmefene hydrochloride dihydrate | |
EA201290552A1 (ru) | Способ производства фармацевтически активного вещества | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
WO2012010669A3 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
PL2217219T3 (pl) | Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną | |
AP2010005389A0 (en) | Nanoparticle carriers for drug administration and process for producing same. | |
EP2408511A4 (en) | APPARATUS FOR DELIVERY OF SOLID MEDICAMENTS, PREPARATIONS AND METHODS OF USE | |
WO2010148314A3 (en) | Preparation of esomeprazole and its pharmaceutically acceptable salts | |
EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
EP2454374A4 (en) | ORAL VACCINES PRODUCED AND ADMINISTERED WITH AN EDIBLE MICROORGANISM | |
GB0920721D0 (en) | An orally administered anthelmintic unit dose tablet and process for the preparation thereof | |
MY197454A (en) | Non-enteric pharmaceutical composition comprising crofelemer | |
MX2013010415A (es) | Tratamiento de la atrofia vaginal con nueva indicacion para la mirra. | |
PH12014501822A1 (en) | Oral formulation comprising lansoprazole and the preparation method thereof | |
TN2015000156A1 (en) | Dispersible tablet | |
WO2011153819A8 (zh) | 用于戒毒的药物组合物 | |
UA69684U (ru) | Способ медицинской реабилитации больных неалкогольным стеатогепатитом, соединенным с дисбиозом кишечника |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |